

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 16952-CON1-CIP3 (BOT)	SERIAL NO.: 10/726,904
APPLICANT: AOKI et al.	TITLE: USE OF THE NEUROTOXIC COMPONENT OF A BOTULINUM TOXIN FOR TREATING VARIOUS DISORDERS AND CONDITIONS AND ASSOCIATED PAIN
FILING DATE: DECEMBER 2, 2003	GROUP: 1654

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
AA						

FOREIGN PATENT DOCUMENTS

DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
BA					

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

CA	"Starkes Toxin hilft bei Blepharospasmus" (October 10, 1987).
CB	"Botulinum-Toxin hilft bei Augenleiden" (December 1986).
CC	Schantz, et al., "Quality of Botulinum Toxin for Human Treatment" <u>Botulinum and Tetanus Neurotoxins</u> , pp. 41-49, (1993).
CD	Schantz, et al., "Preparation and Characterization of Botulinum Toxin Type A for Human Treatment" <u>Therapy with Botulinum Toxin</u> , pp. 657-659, (1994).
CE	Schiavo, et al., "Tetanus and Botulism Neurotoxins: Isolation and Assay" <u>Methods Enzymol</u> , Vol. 248; pp. 643-652, (1995).
CF	Zhang, et al., "Detection of Botulinum Neurotoxin's Enzymatic Activity of Type A Ghuncha Ambrin" <u>Faseb J.</u> , Vol. 18(8); 1 page, (2004).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 16952-CON1-CIP3 (BOT)	SERIAL NO.: 10/726,904
APPLICANT: AOKI et al.	TITLE: USE OF THE NEUROTOXIC COMPONENT OF A BOTULINUM TOXIN FOR TREATING A SPASTIC MUSCLE
FILING DATE: DECEMEBER 2, 2003	GROUP: 1654

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
as	AA	2,373,454	04/10/1945	Bunney, et al.	167	68	07/09/1943
	AB	2,719,102	09/27/1955	Baldwin	167	68	10/28/1949
	AC	3,132,995	05/12/1964	Berger, et al.	167	68	10/20/1961
	AD	4,832,936	05/23/1989	Holter, et al.	423	555	09/21/1987
	AE	4,932,936	06/12/1990	Dykstra, et al.	604	51	01/29/1988
	AF	5,053,005	10/01/1991	Borodic	604	51	04/21/1989
	AG	5,055,302	10/08/1991	Laties, et al.	424	427	02/22/1990
	AH	5,056,291	10/15/1991	Leung, et al.	52	637	10/19/1989
	AI	5,183,462	02/02/1993	Borodic	604	51	08/21/1990
	AJ	5,298,019	03/29/1994	Borodic	604	51	01/13/1993
	AK	5,401,243	03/28/1995	Borodic	604	51	04/12/1993
	AL	5,437,291	08/01/1995	Pasricha, et al.	128	898	08/26/1993
	AM	5,562,907	10/08/1996	Arnon	424	236.1	06/06/1994
	AN	5,766,605	06/16/1998	Sanders, et al.	424	239.1	04/15/1994
	AO	6,290,961	09/18/2001	Aoki, et al.	424	184.1	01/24/2000
as	AP	2002/0102275	08/01/2002	Graham	424	247.1	03/22/2002

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
as	BA	WO 94/28923	12/22/1994	PCT	A61K	37/02	Y
	BB	WO 94/00481	01/06/1994	PCT	A61K	37/02	Y
as	BC	WO 95/28171	10/26/1995	PCT	A61K	38/16	Y

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

as	CA	"Porton Refocuses on Pharmaceuticals" <u>Scrip</u> , No. 1871, 10 (Vol. 9, No. 1993).
	CB	Med. Ad. News Staff, "Athena Makes a Wise Move" <u>Medical Advertising News</u> ; p. 4, (Nov. 1992).
	CC	U.S. Food and Drug Administration, List of Orphan Designations and Approvals; pp. 1 and 42-46, (computer search printout January 18, 2000).
	CD	Adenis, J.P., et al., "Traitement des Spasmes Faciaux Par La Toxine Botulique A" <u>J.Fr. Ophtalmal.</u> , Vol. 13, No. 5; pp. 259-264, (1990).
	CE	Ambache, <u>J. Physiol.</u> , Vol. 108; pp. 127-141, (1949).
as	CF	Ambache, N., "A Further Survey of the Action of Clostridium Botulinum Toxin Upon Different Types of Autonomic Nerve Fibre" <u>J. Physiol.</u> , Vol. 113; pp. 1-17, (1951).

EXAMINER

DATE CONSIDERED 11/20/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 16952-CON1-CIP3 (BOT)	SERIAL NO.: 10/726,904
APPLICANT: AOKI et al.	TITLE: USE OF THE NEUROTOXIC COMPONENT OF A BOTULINUM TOXIN FOR TREATING A SPASTIC MUSCLE
FILING DATE: DECEMEBER 2, 2003	GROUP: 1654

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

CG	Brin, Arch. De Neurobiol., Vol. 54, Supl. 3; pp. 7-23, (1991).
CH	Das, T.K. et al., "Effect of treatment with Botulinum toxin on spasticity" <u>Postgraduate Medical Journal</u> , Vol. 65; pp. 208-210, (1989).
CI	Habermann, "Foreword" <u>Botulinum and Tetanus Neurotoxins</u> , published by Plenum Press; pp. v - ix, (1993).
CJ	Dykstra, D., et al., "Treatment of Detrusor-Sphincter Dyssynergia with Botulinum A Toxin: A Double-Blind Study" <u>Arch. Phys. Med. Rehabil.</u> , Vol. 71; pp. 24-26, (January 1990).
CK	Elston, et al., "Paralytic strabismus: the role of botulinum toxin" <u>Br. J. Ophthalmol.</u> , Vol. 69(12); pp. 891-896, (December 1985), Abstract only.
CL	Foster, K.A., "New Wrinkle On Pain Relief: Re-Engineering Clostridial Neurotoxins for Analgesics" <u>Drug Discovery Today</u> , Vol. 10, No. 8; pp. 563-569, (April 2005).
CM	Greene, Paul, et al., "Response to Botulinum Toxin F in Seronegative Botulinum Toxin A-Resistant Patients" <u>Movement Disorders</u> , Vol. 11, No.2; pp. 181-184, (March 1996).
CN	Greene, et al., "Development of Antibodies to Botulinum Toxin Type A in Patients with Torticollis Treated with Injections of Botulinum Toxin Type A" <u>Botulinum and Tetanus Neurotoxins</u> , Plenum Press; pp. 651-654, (1993).
CO	Hambleton, P. "Clostridium Botulinum Toxins: a general review of involvement in disease, structure, mode of action and preparation for clinical use" <u>J. Neurol.</u> , Vol. 239, No. 1; pp. 16-20, (1992).
CP	Harper, K.E., et al., "Frey's Syndrome" <u>International Journal of Dermatology</u> , Vol. 25, No. 8; pp. 524-526, (October 1986).
CQ	Hatheway, C.L., "Bacterial Sources of Clostridial Neurotoxins" <u>Botulinum Neurotoxin and Tetanus Toxin Academic Press</u> , pp. 4-24, (1989).
CR	Jenzer, et al., <u>Schweiz. Med. Wschr.</u> , Vol. 104; pp. 685-693, with English translation.
CS	Khalafalla, et al., "Botulinum Toxin and Sweating" <u>J. Neurology, Neurosurgery and Psychiatry</u> , Vol. 57; pp. 1437-1438, (1994).
CT	Konstazer, A., et al., "Lokale Injektionsbehandlung mit Botulinum-Toxin A bei schwerer Arm-und Beinspastik" <u>Der Nervenarzt</u> , Vol. 64(8); pp. 517-523, (August 1993).
CU	Laccourreye, et al., "Treatment of Frey's Syndrome in Topical 2% Diphemanyl Methylsulfate (Prantal): A Double-Blind Evaluation of 15 Patients" <u>Laryngoscope</u> , Vol. 100; pp. 651-653, (1990).
CV	Ludlow, et al., "Therapeutic Uses of Type F Botulinum Toxin" <u>Letter to New England Journal of Medicine</u> , Vol. 326, No. 5; pp. 349-350, (January 1992).
CW	Memin, et al., "Traitement de la Spasticité par la Toxine Botulique" <u>Rev. Neurol.</u> , Vol. 148(3); pp. 212-214, (1992).
CX	Montecucco, C., et al., "Botulinum Neurotoxins: Mechanism of Action and Therapeutic Applications," <u>Mol. Med. Today</u> , Vol. 2, No. 10; pp. 418-424, (October 1996).
CY	Moyer, E.D., et al., "Effects of Intramuscular Injection of Botulinum Toxin Type B in Nonhuman Primates" <u>Botulinum and Tetanus Neurotoxins-Neurotransmission and Biomedical Aspects</u> , Bibhuti R. Dasgupta, Editor; Plenum Press, (1993).
CZ	Meyer, E., et al. "Botulinum Toxin Type B: Experimental and Clinical Experience" <u>Therapy with</u>

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 16952-CON1-CIP3 (BOT)	SERIAL NO.: 10/726,904
APPLICANT: AOKI et al.	TITLE: USE OF THE NEUROTOXIC COMPONENT OF A BOTULINUM TOXIN FOR TREATING A SPASTIC MUSCLE
FILING DATE: DECEMEBER 2, 2003	GROUP: 1654

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

00		<u>Botulinum Toxin</u> , Jankovic J. and Hallett, M., ed., Dekker Publishers: New York, NY; pp. 71-85, (February 1994).
	CAA	Poungvarne, et al., <u>J. Med. Assoc. Thai</u> , Vol. 75(4); pp. 199-203, (April 1992).
	CBB	Price, J., et al., "A Comparative-Study of Tear Secretion in Blepharospasm and Hemifacial Spasm Patients Treated with Botulinum Toxin" <u>Journal of Clinical Neuro-Ophthalmology</u> , Vol. 13, No. 1; pp. 67-71, (March 1993), Abstract only.
	CCC	Ransom, G.M., et al., "Enzyme-Linked Immunosorbent Assays (ELISAs) to Detect Botulinum Toxins Using High Titer Rabbit Anti-Sera" <u>Botulinum and Tetanus Neurotoxins</u> , Plenum Press; pp. 449-462, (1993).
	CDD	Ruusuvuura, P and Setälä, K., "Long-term Treatment of Involuntary Facial Spasms Using Botulinum Toxin" <u>Acta Ophthalmol.</u> , Vol. 68; pp. 331-338, (1990).
	CEE	Saga, T., et al., "Secretion of Tears in Patients with Hemifacial Spasm" <u>Jpn. J. Ophthalmol.</u> , Vol. 34; pp. 30-35, (1990).
	CFE	Schurch, B., et al., "Effets de la Toxine Botulinique A sur le sphincter strié périurétral des vessies neurogènes" <u>Journal d'Urologie</u> , Vol. 96(7); pp. 375-380, (1990).
	CGG	Scott, Alan B., et al., "Systemic Toxicity of Botulinum Toxin by Intramuscular Injection in the Monkey", <u>Movement Disorders</u> , Vol. 3, No. 4; pp. 333-335, (1988).
	CHH	Scott, Alan B., "A Clinical Preface" <u>Botulinum and Tetanus Neurotoxins</u> , Plenum Press; pp. 557-558, (1993).
	CII	Tang-Liu, D., et al., "Intramuscular Injection of ¹²⁵ I-botulinum Neurotoxin-Complex Versus ¹²⁵ I-botulinum-free Neurotoxin: Time Course of Tissue Distribution" <u>Toxicon</u> , Vol. 42; pp. 461-489, (2003).
	CJJ	Truong, Daniel D., et al., "BotB (Botulinum Toxin Type B): Evaluation of Safety and Tolerability in Botulinum Toxin Type A-Resistant Cervical Dystonia Patients" <u>Movement Disorders</u> , Vol. 12, No. 5; pp. 772-775, (September 1997).
	CKK	Tsui, J.K., et al., "A Pilot Study on the Use of Botulinum Toxin in Spasmodic Torticollis" <u>Can. J. Neurol. Sci.</u> , Vol. 13, No. 4; pp. 314-316, (1985).
	CLL	Tsui, Joseph K.C., et al., "Local Treatment Spasmodic Torticollis with Botulinum Toxin" <u>Le Journal Canadien des Sciences Neurologiques</u> , Vol. 14, No. 3; pp. 533-535, (August 1987).
	CMM	Wainwright, R.B., et al., "Food-Borne Botulism in Alaska, 1947-1985: Epidemiology and Clinical Findings" <u>J. Infect. Dis.</u> , Vol. 157, No. 6; pp. 1158-1162, (1988).
02	CNN	Wohlfarth, et al., "Pharmacokinetic Properties of Different Formulations of Botulinum Neurotoxin Type A" <u>Naunyn-Schmiedeberg's Arch. Pharmacol.</u> , Vol. 365 (Supp 2), R48, (2002).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.